TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB)
Brief Summary: The primary objective of this study is to assess the efficacy of SIRT as compared with Sorafenib in patients with locally advanced liver cancer in terms of overall survival (OS).

The Study null hypothesis is, there is no difference in overall survival between patients receiving SIRT and those receiving Sorafenib therapy.


Options:
A: Intervention Type: DEVICE; Name: Yttrium-90 microspheres (Therasphere MDS Nordion); Assigned to Arm(s): N/A
B: Arm Label: Sorafenib, Multikinase Inhibitor, Tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib tosylate | Arm Label: SIR-Spheres, Microspheres, Device; Type: ACTIVE_COMPARATOR; Interventions: Device: SIR-Spheres | Intervention Type: DEVICE; Name: SIR-Spheres; Assigned to Arm(s): SIR-Spheres, Microspheres, Device | Intervention Type: DRUG; Name: Sorafenib tosylate; Assigned to Arm(s): Sorafenib, Multikinase Inhibitor, Tablet
C: Arm Label: sorafenib group; Type: ACTIVE_COMPARATOR; Interventions: Drug: sorafenib | Arm Label: radioembolization group; Type: ACTIVE_COMPARATOR; Interventions: Drug: SIR-Sphere | Intervention Type: DRUG; Name: sorafenib; Assigned to Arm(s): sorafenib group | Intervention Type: DRUG; Name: SIR-Sphere; Assigned to Arm(s): radioembolization group
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: E-Coaching: IVR-Enhanced Care Transition Support for Complex Patients
Brief Summary: For complex medical patients, the transition from hospital to home-based care is a vulnerable period, placing the patient at high risk for adverse events. Using a Care Transition conceptual model, the investigators propose developing and evaluating, through a randomized controlled trial, "e-Coach," an Interactive-Voice-Response-supported (IVR) Care Transition coaching intervention, focused initially on patients hospitalized with heart failure or obstructive lung disease. This trial will test the primary hypothesis that the proportion of patients with one or more re-hospitalizations during a 90-day post-discharge follow-up period will be less in an IVRsupported care transition intervention (e-Coach) compared to a "usual care" comparison group.


Options:
A: Arm Label: CHF patients, IVR-Enhanced Care; Type: EXPERIMENTAL; Interventions: Behavioral: IVR-Enhanced Care | Arm Label: COPD patients, IVR-Enhanced Care; Type: EXPERIMENTAL; Interventions: Behavioral: IVR-Enhanced Care | Arm Label: CHF patients, Usual Discharge Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: COPD patients, Usual Discharge Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: IVR-Enhanced Care; Assigned to Arm(s): CHF patients, IVR-Enhanced Care, COPD patients, IVR-Enhanced Care
B: Arm Label: Tiotropium low; Type: EXPERIMENTAL; Interventions: Drug: Tiotropium low | Arm Label: Tiotropium medium; Type: EXPERIMENTAL; Interventions: Drug: Tiotropium medium | Arm Label: Tiotropium high; Type: EXPERIMENTAL; Interventions: Drug: Tiotropium high | Arm Label: Tiotropium 18mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18mcg | Arm Label: Tiotropium placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tiotropium placebo | Intervention Type: DRUG; Name: Tiotropium medium; Assigned to Arm(s): Tiotropium medium | Intervention Type: DRUG; Name: Tiotropium low; Assigned to Arm(s): Tiotropium low | Intervention Type: DRUG; Name: Tiotropium high; Assigned to Arm(s): Tiotropium high | Intervention Type: DRUG; Name: Tiotropium 18mcg; Assigned to Arm(s): Tiotropium 18mcg | Intervention Type: DRUG; Name: Tiotropium placebo; Assigned to Arm(s): Tiotropium placebo
C: Intervention Type: BEHAVIORAL; Name: Self-management of chronic illness; Assigned to Arm(s): N/A
D: Arm Label: Pharmaceutical care program; Type: EXPERIMENTAL; Interventions: Other: Pharmaceutical Care Program | Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard Care | Intervention Type: OTHER; Name: Pharmaceutical Care Program; Assigned to Arm(s): Pharmaceutical care program | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: E-Coaching: IVR-Enhanced Care Transition Support for Complex Patients
Brief Summary: For complex medical patients, the transition from hospital to home-based care is a vulnerable period, placing the patient at high risk for adverse events. Using a Care Transition conceptual model, the investigators propose developing and evaluating, through a randomized controlled trial, "e-Coach," an Interactive-Voice-Response-supported (IVR) Care Transition coaching intervention, focused initially on patients hospitalized with heart failure or obstructive lung disease. This trial will test the primary hypothesis that the proportion of patients with one or more re-hospitalizations during a 90-day post-discharge follow-up period will be less in an IVRsupported care transition intervention (e-Coach) compared to a "usual care" comparison group.


Options:
A: Arm Label: Remote-Monitoring Program; Type: EXPERIMENTAL; Interventions: Device: Cloud Dx Kit with remote-monitoring | Arm Label: Self-Monitoring Program; Type: EXPERIMENTAL; Interventions: Device: Cloud Dx Kit with self-monitoring | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Cloud Dx Kit with self-monitoring; Assigned to Arm(s): Self-Monitoring Program | Intervention Type: DEVICE; Name: Cloud Dx Kit with remote-monitoring; Assigned to Arm(s): Remote-Monitoring Program
B: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Coaching program; Type: EXPERIMENTAL; Interventions: Other: Coaching program | Intervention Type: OTHER; Name: Coaching program; Assigned to Arm(s): Coaching program
C: Arm Label: CHF patients, IVR-Enhanced Care; Type: EXPERIMENTAL; Interventions: Behavioral: IVR-Enhanced Care | Arm Label: COPD patients, IVR-Enhanced Care; Type: EXPERIMENTAL; Interventions: Behavioral: IVR-Enhanced Care | Arm Label: CHF patients, Usual Discharge Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: COPD patients, Usual Discharge Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: IVR-Enhanced Care; Assigned to Arm(s): CHF patients, IVR-Enhanced Care, COPD patients, IVR-Enhanced Care
D: Arm Label: Tool + Self-management Support Program; Type: EXPERIMENTAL; Interventions: Device: Tool, Behavioral: Self-management Support Program | Arm Label: Self- management Support Program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management Support Program | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Tool; Assigned to Arm(s): Tool + Self-management Support Program | Intervention Type: BEHAVIORAL; Name: Self-management Support Program; Assigned to Arm(s): Self- management Support Program, Tool + Self-management Support Program

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: E-Coaching: IVR-Enhanced Care Transition Support for Complex Patients
Brief Summary: For complex medical patients, the transition from hospital to home-based care is a vulnerable period, placing the patient at high risk for adverse events. Using a Care Transition conceptual model, the investigators propose developing and evaluating, through a randomized controlled trial, "e-Coach," an Interactive-Voice-Response-supported (IVR) Care Transition coaching intervention, focused initially on patients hospitalized with heart failure or obstructive lung disease. This trial will test the primary hypothesis that the proportion of patients with one or more re-hospitalizations during a 90-day post-discharge follow-up period will be less in an IVRsupported care transition intervention (e-Coach) compared to a "usual care" comparison group.


Options:
A: Arm Label: CHF patients, IVR-Enhanced Care; Type: EXPERIMENTAL; Interventions: Behavioral: IVR-Enhanced Care | Arm Label: COPD patients, IVR-Enhanced Care; Type: EXPERIMENTAL; Interventions: Behavioral: IVR-Enhanced Care | Arm Label: CHF patients, Usual Discharge Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: COPD patients, Usual Discharge Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: IVR-Enhanced Care; Assigned to Arm(s): CHF patients, IVR-Enhanced Care, COPD patients, IVR-Enhanced Care
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Multi-component physical activity counseling program | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multi-component physical activity counseling program; Assigned to Arm(s): Arm 1
C: Arm Label: 1 concurrent smoking cessation; Type: EXPERIMENTAL; Interventions: Behavioral: behavioral counseling plus contingency management | Arm Label: 2 deferred smoking cessation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: behavioral counseling plus contingency management | Intervention Type: BEHAVIORAL; Name: behavioral counseling plus contingency management; Assigned to Arm(s): 1 concurrent smoking cessation, 2 deferred smoking cessation
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care and Reading Materials | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Modification Program | Intervention Type: BEHAVIORAL; Name: Lifestyle Modification Program; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Usual Care and Reading Materials; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sevelamer, FGF-23 and Endothelial Dysfunction in CKD
Brief Summary: Vascular calcification and endothelial dysfunction (ED) contribute to the development of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). Sevelamer, a non-calcium based phosphate binder, has been shown to attenuate cardiovascular calcification in CKD patients while the exact mechanism has not been clarified.

This study was designed to investigate the effect of short-term sevelamer treatment on both serum FGF23 levels concentrations and ED seen in CKD patients.

The researchers investigated the relationship between plasma FGF23 levels and the forearm blood flow response to ischemia in the forearm in a sizable series of incident stage 3-4 CKD patients.


Options:
A: Arm Label: Sevelamer; Type: OTHER; Interventions: Drug: Sevelamer, Drug: calcium acetate | Arm Label: calcium acetate; Type: OTHER; Interventions: Drug: calcium acetate | Intervention Type: DRUG; Name: Sevelamer; Assigned to Arm(s): Sevelamer | Intervention Type: DRUG; Name: calcium acetate; Assigned to Arm(s): Sevelamer, calcium acetate
B: Arm Label: Sevelamer; Type: EXPERIMENTAL; Interventions: Drug: Sevelamer | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sevelamer; Assigned to Arm(s): Sevelamer | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Active Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo | Arm Label: KRX-0502 (Ferric Citrate); Type: EXPERIMENTAL; Interventions: Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo | Intervention Type: DRUG; Name: ferric citrate, ca acetate, sevelamer carbonate, placebo; Assigned to Arm(s): Active Control, KRX-0502 (Ferric Citrate), Placebo
D: Arm Label: Chewing Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum | Arm Label: Chewing Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Other: K2CG chewing gum | Arm Label: Chewing Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum | Arm Label: Chewing Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum | Intervention Type: OTHER; Name: K2CG chewing gum; Assigned to Arm(s): Chewing Arm 1, Chewing Arm 2, Chewing Arm 3, Chewing Arm 4 | Intervention Type: OTHER; Name: K2CG chewing gum; Assigned to Arm(s): Chewing Arm 1, Chewing Arm 2, Chewing Arm 3, Chewing Arm 4 | Intervention Type: OTHER; Name: K2CG chewing gum; Assigned to Arm(s): Chewing Arm 1, Chewing Arm 2, Chewing Arm 3, Chewing Arm 4 | Intervention Type: OTHER; Name: K2CG chewing gum; Assigned to Arm(s): Chewing Arm 1, Chewing Arm 2, Chewing Arm 3, Chewing Arm 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Alcohol SBIRT Implementation in an HMO: Non-Physician Providers Vs Physicians
Brief Summary: The purpose of this study is to determine whether Alcohol Screening, Brief Intervention, and Referral to Specialty Chemical Dependency Treatment (as appropriate) by Non-Physicians versus Primary Care Providers (versus control group) is more likely to be implemented and more effective at reducing unsafe drinking.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Driving in Mild Dementia Decision Tool | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Driving in Mild Dementia Decision Tool; Assigned to Arm(s): Intervention
B: Arm Label: Non-Physician Provider; Type: EXPERIMENTAL; Interventions: Other: Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Primary Care Provider; Type: ACTIVE_COMPARATOR; Interventions: Other: Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment | Intervention Type: OTHER; Name: Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment; Assigned to Arm(s): Non-Physician Provider, Primary Care Provider
C: Arm Label: iCPR randomized providers; Type: EXPERIMENTAL; Interventions: Other: Integrated Clinical Prediction Rule (iCPR) | Arm Label: Control providers; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Integrated Clinical Prediction Rule (iCPR); Assigned to Arm(s): iCPR randomized providers
D: Arm Label: Electronic alert; Type: ACTIVE_COMPARATOR; Interventions: Other: Electronic warning alert | Arm Label: No electronic alert; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic warning alert; Assigned to Arm(s): Electronic alert

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of High Dose N-acetylcysteine on Airtrapping and Airway Resistance of Chronic Obstructive Pulmonary disease-a Double Blinded Randomized Placebo Controlled Trial
Brief Summary: This study is to investigate the add-on effect of high dose NAC (600mg tablet twice daily) on reduction of airtrapping and airway resistance in stable COPD patients as well as to study it's effect in reducing exacerbation, improving exercise capacity and quality of life in stable COPD patients.


Options:
A: Arm Label: Pedometer-based activity promotion; Type: EXPERIMENTAL; Interventions: Behavioral: Pedometer-based activity promotion, Other: Pulmonary rehabilitation (Standard care) | Arm Label: Short patient education and exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Short patient education and exercise, Other: Pulmonary rehabilitation (Standard care) | Intervention Type: BEHAVIORAL; Name: Pedometer-based activity promotion; Assigned to Arm(s): Pedometer-based activity promotion | Intervention Type: BEHAVIORAL; Name: Short patient education and exercise; Assigned to Arm(s): Short patient education and exercise | Intervention Type: OTHER; Name: Pulmonary rehabilitation (Standard care); Assigned to Arm(s): Pedometer-based activity promotion, Short patient education and exercise
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: N-acetylcysteine; Type: ACTIVE_COMPARATOR; Interventions: Drug: N-acetycysteine (600mg twice daily) | Intervention Type: DRUG; Name: N-acetycysteine (600mg twice daily); Assigned to Arm(s): N-acetylcysteine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Urban training Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Urban training | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Urban training; Assigned to Arm(s): Urban training Intervention
D: Arm Label: neuromuscular electrical stimulation; Type: EXPERIMENTAL; Interventions: Device: neuromuscular electrical stimulation, Other: Conventional pulmonary rehabilitation | Arm Label: cycle ergometer training; Type: EXPERIMENTAL; Interventions: Device: cycle ergometer training, Other: Conventional pulmonary rehabilitation | Intervention Type: DEVICE; Name: neuromuscular electrical stimulation; Assigned to Arm(s): neuromuscular electrical stimulation | Intervention Type: DEVICE; Name: cycle ergometer training; Assigned to Arm(s): cycle ergometer training | Intervention Type: OTHER; Name: Conventional pulmonary rehabilitation; Assigned to Arm(s): cycle ergometer training, neuromuscular electrical stimulation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
Brief Summary: This is an open-label, multicenter, Phase 1b/2 study of lenvatinib alone and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-targeted treatment.


Options:
A: Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: IMA901 plus GM-CSF added to sunitinib after single dose of cy; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib, Biological: GM-CSF, Drug: Cyclophosphamide, Drug: IMA901 | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy, Sunitinib | Intervention Type: BIOLOGICAL; Name: GM-CSF; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy | Intervention Type: DRUG; Name: IMA901; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy
B: Arm Label: Sorafenib (Nexavar, BAY43-9006); Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sorafenib (Nexavar, BAY43-9006); Assigned to Arm(s): Sorafenib (Nexavar, BAY43-9006) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: everolimus 1L/sunitinib 2L; Type: EXPERIMENTAL; Interventions: Drug: everolimus, Drug: sunitinib | Arm Label: sunitinib 1L/everolimus 2L; Type: ACTIVE_COMPARATOR; Interventions: Drug: everolimus, Drug: sunitinib | Intervention Type: DRUG; Name: everolimus; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L | Intervention Type: DRUG; Name: sunitinib; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L
D: Arm Label: Lenvatinib; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib | Arm Label: Lenvatinib plus Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Everolimus | Arm Label: Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: Lenvatinib; Assigned to Arm(s): Lenvatinib, Lenvatinib plus Everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus, Lenvatinib plus Everolimus

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Felodipine Event Reduction Study
Brief Summary: FEVER is an investigator-designed, prospective, multicentre,double-bind, randomized, placebo-controlled,parallel-group trial. The primary objective is to compare the long-term effects on the incidence of fatal and non-fatal stroke (and secondarily of other cardiovascular events) of administering a small dose of the calcium antagonist felodipine (5 mg once a day) or of a placebo, in hypertensive patients whose blood pressure had preliminarily been reduced by administering a low-dose diuretic (hydrochlorothiazide,12.5 mg once a day) to be continued in association with felodipine or placebo, throughout the trial.


Options:
A: Arm Label: felodipine group, active, pill; Type: ACTIVE_COMPARATOR; Interventions: Drug: Felodipine | Arm Label: placebo, no treatment, pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Felodipine; Assigned to Arm(s): felodipine group, active, pill | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo, no treatment, pill
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Multifactorial vascular-risk-factor-intervention | Intervention Type: OTHER; Name: Multifactorial vascular-risk-factor-intervention; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Indapamide SR 1.5mg; Perindopril 2-4mg; Assigned to Arm(s): N/A
D: Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP control | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Intervention Type: DRUG; Name: Intensive BP control; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Felodipine Event Reduction Study
Brief Summary: FEVER is an investigator-designed, prospective, multicentre,double-bind, randomized, placebo-controlled,parallel-group trial. The primary objective is to compare the long-term effects on the incidence of fatal and non-fatal stroke (and secondarily of other cardiovascular events) of administering a small dose of the calcium antagonist felodipine (5 mg once a day) or of a placebo, in hypertensive patients whose blood pressure had preliminarily been reduced by administering a low-dose diuretic (hydrochlorothiazide,12.5 mg once a day) to be continued in association with felodipine or placebo, throughout the trial.


Options:
A: Intervention Type: DRUG; Name: valsartan; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Tablets | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Tablets; Assigned to Arm(s): 2
C: Arm Label: felodipine group, active, pill; Type: ACTIVE_COMPARATOR; Interventions: Drug: Felodipine | Arm Label: placebo, no treatment, pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Felodipine; Assigned to Arm(s): felodipine group, active, pill | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo, no treatment, pill
D: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A

Answer: C